Key Highlights

  • The SANRECO Phase 2 trial reportedly showed an 88% response rate.
  • The company priced an upsized public offering of about $175 million in August.
  • Cash was $72.1 million at June 30, before the offering.
  • The next report is estimated for November 5, 2026.

Silence Therapeutics Plc (NASDAQ:SLN), whose American depositary shares trade in US dollars, has been in focus after reporting positive topline Phase 2 results for divesiran in polycythemia vera and raising capital. It has a market capitalisation near $573 million.

Latest Company Context

The SANRECO Phase 2 trial reportedly showed an 88% response rate versus 18% for placebo. The company priced an upsized public offering of about $175 million in August, closed with the underwriters' option fully exercised. Q2 2026 results, released August 10, showed cash of $72.1 million at June 30, before the offering, and an EPS of -$0.09 versus a -$0.17 consensus estimate. FY2025 revenue was $559,000 and the loss $88.6 million. Morgan Stanley raised its target to $32 from $25 (Overweight), and Cantor Fitzgerald initiated at Overweight. The next report is estimated for November 5, 2026.

Key Business Drivers

The pipeline is built on siRNA technology: divesiran (SLN124) with Phase 3 planned and quarterly dosing, SLN548 for complement-mediated renal disease, zerlasiran (SLN360) for elevated lipoprotein(a), SLN312 for dyslipidaemia and preclinical SLN365. Value is largely driven by clinical and regulatory progress, so the stock may react strongly to trial news. The offering extends funding but increases the share count.

What Investors Should Watch

Investors may watch Phase 3 design and start timing for divesiran, regulatory feedback, updates on zerlasiran and other programmes, partnering news, and the November results, which should include post-offering cash and expected runway. Detailed presentation of full SANRECO data at medical meetings could also be a catalyst.

Positive Phase 2 Data and Fresh Capital

Silence combined positive Phase 2 data with an upsized raise that was fully exercised. Morgan Stanley's raised target and Cantor Fitzgerald's initiation add analyst attention ahead of the November 5 report.